235 related articles for article (PubMed ID: 24165088)
1. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
Iyer AV; Pahar B; Chouljenko VN; Walker JD; Stanfield B; Kousoulas KG
Virol J; 2013 Oct; 10():317. PubMed ID: 24165088
[TBL] [Abstract][Full Text] [Related]
2. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
[TBL] [Abstract][Full Text] [Related]
3. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
[TBL] [Abstract][Full Text] [Related]
5. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.
Burn C; Ramsey N; Garforth SJ; Almo S; Jacobs WR; Herold BC
J Infect Dis; 2018 Feb; 217(5):754-758. PubMed ID: 29216362
[TBL] [Abstract][Full Text] [Related]
6. Progesterone increases susceptibility and decreases immune responses to genital herpes infection.
Kaushic C; Ashkar AA; Reid LA; Rosenthal KL
J Virol; 2003 Apr; 77(8):4558-65. PubMed ID: 12663762
[TBL] [Abstract][Full Text] [Related]
7. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.
Reszka NJ; Dudek T; Knipe DM
Vaccine; 2010 Mar; 28(15):2754-62. PubMed ID: 20117270
[TBL] [Abstract][Full Text] [Related]
8. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
[TBL] [Abstract][Full Text] [Related]
10. A herpes simplex virus 1 (McKrae) mutant lacking the glycoprotein K gene is unable to infect via neuronal axons and egress from neuronal cell bodies.
David AT; Saied A; Charles A; Subramanian R; Chouljenko VN; Kousoulas KG
mBio; 2012; 3(4):e00144-12. PubMed ID: 22829677
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
12. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
13. Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease.
Sato A; Suwanto A; Okabe M; Sato S; Nochi T; Imai T; Koyanagi N; Kunisawa J; Kawaguchi Y; Kiyono H
J Virol; 2014 Dec; 88(23):13699-708. PubMed ID: 25231301
[TBL] [Abstract][Full Text] [Related]
14. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
[TBL] [Abstract][Full Text] [Related]
15. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
[TBL] [Abstract][Full Text] [Related]
16. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K.
Ghiasi H; Slanina S; Nesburn AB; Wechsler SL
J Virol; 1994 Apr; 68(4):2347-54. PubMed ID: 8139020
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
19. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
[TBL] [Abstract][Full Text] [Related]
20. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
